Addus HomeCare stock hits 52-week low at 91.1 USD By Investing.com
Addus HomeCare (ADUS) stock has recently fallen to a 52-week low of $91.10, representing a 5.58% decrease over the past year. Despite the decline, InvestingPro analysis suggests the stock is undervalued, with a P/E ratio of 17.56 and a PEG ratio of 0.74, and its RSI indicates it is in oversold territory. The company remains profitable with 23% revenue growth over the last twelve months, and analysts maintain generally positive ratings with price targets ranging from $135 to $150.
Addus HomeCare stock hits 52-week low at 91.1 USD By Investing.com
Addus HomeCare (ADUS) stock recently hit a 52-week low of $91.10, representing a 5.58% decrease over the past year. Despite this, InvestingPro analysis suggests the stock is undervalued, with an RSI indicating oversold conditions, potentially signaling a buying opportunity. The company remains profitable with 23% revenue growth, and analysts have mixed but generally positive ratings, highlighting strong segment growth and demand for its services.
JPMorgan Chase & Co. Sells 34,750 Shares of Addus HomeCare Corporation $ADUS
JPMorgan Chase & Co. reduced its stake in Addus HomeCare Corporation (NASDAQ:ADUS) by 44.2%, selling 34,750 shares and retaining 43,802 shares valued at $5.17 million. Despite this, other institutional investors have increased their holdings, and the company has a "Moderate Buy" consensus rating from analysts with an average price target of $133.22. Additionally, company insiders, including CEO R. Dirk Allison, have sold shares totaling approximately $1.77 million in the last three months.
ADUS Stock News Today | Earnings, Events & Price Alerts
This page provides a consolidated view of news and events related to ADUS (Addus HomeCare) stock, featuring recent headlines on investor conferences, Q4 2025 earnings, and stock price fluctuations. It also includes an events section noting a significant drop in ADUS share price on February 24, 2026. The content highlights financial updates and upcoming engagements for Addus HomeCare, gathered from various financial news sources.
A Look At Addus HomeCare (ADUS) Valuation After The Recent Share Price Pullback
Addus HomeCare (ADUS) has experienced a recent stock price pullback but is still seen as significantly undervalued by analysts, trading at US$95.19 against a fair value of $142.91. This valuation is based on strong organic growth in personal care, strategic acquisitions, and future earnings potential, although it depends on supportive reimbursement policies and controlled wage pressures. The article encourages investors to look beyond headlines and examine the company's fundamentals and potential risks.
ADUS Stock Price, Quote & Chart | ADDUS HOMECARE CORP (NASDAQ:ADUS)
This article provides a comprehensive overview of ADDUS HOMECARE CORP (NASDAQ:ADUS) stock, including its current price, performance, key statistics, and technical and fundamental analysis ratings from ChartMill. It highlights a recent earnings report, analyst forecasts, and company profile details. The stock is currently trading at $95.19, down 2.54% today, with analysts expecting a 50.26% price increase over the next year.
Addus HomeCare stock hits 52-week low at 94.68 USD By Investing.com
Addus HomeCare Corporation (ADUS) stock has fallen to a 52-week low of $94.68, marking a significant drop despite analysts suggesting it is undervalued with price targets up to $160. The company's 1-year change is -1.94%, reflecting broader healthcare sector challenges. Despite this, InvestingPro data indicates an attractive P/E ratio of 18.67 and a PEG ratio of 0.8, suggesting potential for growth, while recent Q4 results showed improved margins and strong growth in Personal Care and Hospice segments.
Addus HomeCare stock hits 52-week low at 94.68 USD
Addus HomeCare (ADUS) stock has fallen to a 52-week low of $94.68, reflecting broader healthcare sector challenges despite some positive analyst sentiment. InvestingPro data suggests the stock is undervalued with analyst price targets up to $160, and mentions solid Q4 results with improved margins and growth in Personal Care and Hospice segments. Analysts from Truist Securities, KeyBanc, and RBC Capital have reiterated "Buy" or "Outperform" ratings, while Stephens and Citizens offer varying perspectives and price targets.
Addus HomeCare Corporation (NASDAQ:ADUS) Receives Consensus Rating of "Moderate Buy" from Analysts
Addus HomeCare Corporation (NASDAQ:ADUS) has received a consensus "Moderate Buy" rating from eleven analysts, with an average 12-month target price of $133.22. Shares opened at $97.67, significantly below this target. Recent insider selling has occurred, but institutional ownership remains high at approximately 95.35%.
Vanguard disaggregates holdings, reports 0 shares in Addus (ADUS)
Vanguard has filed an amended Schedule 13G for Addus HomeCare Corp (ADUS), reporting 0 shares and 0% beneficial ownership. This change is due to an internal realignment on January 12, 2026, which led to certain Vanguard subsidiaries and business divisions reporting their holdings separately. The filing clarifies that this is an administrative reporting detail and not an indication of a trade or change in company control.
Addus HomeCare (NASDAQ:ADUS) Rating Lowered to "Buy" at Wall Street Zen
Wall Street Zen has downgraded Addus HomeCare (NASDAQ:ADUS) from a "strong-buy" to a "buy" rating, though the consensus among analysts remains a "Moderate Buy" with an average price target of $134.33. The article highlights recent insider selling by the CEO and EVP, totaling approximately $1.77 million over 90 days, while institutional investors and hedge funds maintain a significant 95.35% ownership. Addus HomeCare, a provider of home and community-based care services, trades with a market capitalization of $1.85 billion and a P/E ratio of 19.06.
ADUS PE Ratio & Valuation, Is ADUS Overvalued
Addus Homecare Corp (ADUS) is currently considered undervalued based on its forward P/E ratio of 15.91, which is below its five-year average of 21.57. The fair price for ADUS is estimated to be between $212.37 and $246.98, significantly higher than its current price of $100.94. This suggests the stock is undervalued by 52.47% according to a relative valuation method.
Addus HomeCare at Oppenheimer Conference: Strategic Growth Insights
Addus HomeCare (NASDAQ:ADUS) presented at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, outlining a promising strategic outlook focused on growth in Medicaid-supported services and potential acquisitions. Despite challenges like state budget pressures and home health volume issues, the company targets 3%-5% same-store growth for 2026, driven by strong rate support and leveraging technology for efficiency. Executives also discussed their comfort with fraud and abuse scrutiny due to robust compliance and their role as a cost-effective alternative within the Medicaid framework.
51,491 Shares in Addus HomeCare Corporation $ADUS Purchased by 8 Knots Management LLC
8 Knots Management LLC recently acquired 51,491 shares of Addus HomeCare Corporation (NASDAQ:ADUS) in Q3, making it a new $6.08 million stake and their 18th-largest holding. This institutional buying comes as company insiders, including EVPs Brian Poff and David W. Tucker, sold shares totaling about $1.79 million in the last quarter, bringing insider ownership to approximately 4.5%. Analysts currently rate ADUS as a "Moderate Buy" with a consensus price target of $134.33.
Short Interest in Addus HomeCare Corporation (NASDAQ:ADUS) Decreases By 18.8%
Short interest in Addus HomeCare Corporation (NASDAQ:ADUS) decreased by 18.8% to 933,071 shares as of February 27th, representing 5.3% of shares sold short and a short-interest ratio of 3.7 days. The company has an average analyst rating of "Moderate Buy" with a consensus target price of $134.33, despite recent insider share sales totaling approximately $1.79 million. Institutional investors hold a significant 95.35% stake in the company.
Addus HomeCare (NASDAQ: ADUS) updates 10-K and adds governance policies
Addus HomeCare Corporation filed an Amendment No. 1 to its annual report (Form 10-K/A) for the fiscal year ended December 31, 2025. This amendment primarily updates the cover page and exhibit list, specifically incorporating the company's Insider Trading Policy and Compensation Recoupment Policy which were previously omitted. The filing also includes updated CEO and CFO certifications, but explicitly states that no consolidated financial statements are included and the amendment does not modify other disclosures in the original annual report.
Capital Research Global Investors Purchases 99,262 Shares of Addus HomeCare Corporation $ADUS
Capital Research Global Investors increased its stake in Addus HomeCare Corporation by 9.0% in the third quarter, acquiring an additional 99,262 shares. Other institutional investors also adjusted their positions, while company insiders, including the CEO and EVP, sold shares totaling over $1.7 million in the last ninety days. Analysts currently have a "Moderate Buy" rating for Addus HomeCare, with a consensus target price of $134.33.
Addus HomeCare (Nasdaq:ADUS) - Stock Analysis
This Simply Wall St analysis of Addus HomeCare (ADUS) highlights its position as a provider of personal care services, with a market cap of US$1.9 billion. The report assesses its valuation, future growth, past performance, financial health, dividends, management, and ownership, and includes analyst insights and recent news. ADUS is noted for its consistent revenue growth, profitability, and strong balance sheet, with earnings forecast to grow 11.5% annually.
Addus HomeCare to Participate in Upcoming March Investor Conferences
Addus HomeCare Corporation announced its participation in two upcoming investor conferences in March 2026. CEO Dirk Allison and CFO Brian Poff will represent the company at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference and the KeyBanc Capital Markets Healthcare Forum, delivering virtual presentations. Live broadcasts and replays of these presentations will be accessible on the company's website.
Home care provider Addus to stream two March investor talks live
Addus HomeCare Corporation (Nasdaq: ADUS) announced its participation in two upcoming virtual investor conferences in March: the Oppenheimer 36th Annual Healthcare MedTech & Services Conference and the KeyBanc Capital Markets Healthcare Forum. Company executives Dirk Allison and Brian Poff will deliver presentations, which will be live-streamed and available for replay on the company's website. Addus HomeCare provides essential home care services, including personal care, hospice, and home health services, to approximately 62,500 patients across 23 states.
A Look At Addus HomeCare (ADUS) Valuation After Strong Earnings And Acquisition-Fueled Growth
Addus HomeCare (ADUS) has reported strong fourth-quarter and full-year net income, with increased diluted earnings per share, yet its short-term share price momentum has been soft. Despite a recent decline in share price, the company is considered undervalued with a fair value of $142.91, driven by strategic acquisitions and projected revenue and cost synergies. Investors are encouraged to review the company's financials for potential opportunities, as the market might not yet fully price in future growth.
How Addus HomeCare’s 2025 Earnings Jump and 2026 M&A Plans Will Impact Addus HomeCare (ADUS) Investors
Addus HomeCare reported strong fourth-quarter and full-year 2025 earnings, with net income of US$29.78 million and US$95.91 million respectively, and diluted EPS rising to US$1.61 for the quarter and US$5.22 for the year. Management plans to pursue selective acquisitions in 2026, leveraging its robust capital structure. Despite strong growth and M&A plans, the company still faces risks from potential reimbursement pressure in Medicare and Medicaid.
How Addus HomeCare’s 2025 Earnings Jump and 2026 M&A Plans Will Impact Addus HomeCare (ADUS) Investors
Addus HomeCare Corporation reported strong fourth-quarter and full-year 2025 net income and earnings per share, with diluted EPS rising to US$1.61 for Q4 and US$5.22 for the year. Management indicated plans for selective 2026 acquisitions, funded by its existing capital structure, and noted continued focus on expansion. This improved financial performance, coupled with strategic acquisition plans, reinforces Addus HomeCare’s investment appeal, despite ongoing reimbursement pressures in Medicare and Medicaid.
Vanguard Group Inc. Grows Position in Addus HomeCare Corporation $ADUS
Vanguard Group Inc. increased its stake in Addus HomeCare Corporation (NASDAQ:ADUS) by 2.9% in the third quarter, now owning 1,298,104 shares valued at over $153 million. Despite significant institutional investment, company insiders have sold over 16,000 shares in the last 90 days. Analysts maintain a "Moderate Buy" rating for ADUS, with an average price target of $134.33, while the stock currently trades around $103.36.
Q4 Earnings Roundup: Addus HomeCare (NASDAQ:ADUS) And The Rest Of The Senior Health, Home Health & Hospice Segment
This article provides a Q4 earnings roundup for Addus HomeCare (NASDAQ:ADUS) and other companies in the senior health, home health, and hospice segment. While Addus HomeCare reported revenue growth in line with expectations, its stock declined. The article highlights BrightSpring Health Services (NASDAQ:BTSG) as the best performer with strong revenue beats, and Chemed (NYSE:CHE) as the weakest, missing analyst estimates.
Addus HomeCare Corporation (ADUS) Stock Analysis: Potential 33% Upside for Savvy Investors
Addus HomeCare Corporation (ADUS) is a significant player in the healthcare sector, focusing on care for the elderly, chronically ill, and disabled. The company's stock shows a reasonable valuation with strong revenue growth and significant analyst support, indicating a potential upside of 33.22%. Despite not offering dividends, its strategic market positioning and reinvestment in growth make ADUS an appealing option for growth-focused investors.
Addus HomeCare Corporation (NASDAQ:ADUS) Short Interest Update
Addus HomeCare Corporation (NASDAQ:ADUS) saw a significant increase in short interest in February, rising by 23.5% to 1,148,513 shares, resulting in a short-interest ratio of 4.6 days. Analysts currently rate the stock as a "Moderate Buy" with a consensus target price of $134.33, while company insiders have recently sold shares. Institutional investors have also been modifying their holdings in the company.
Addus HomeCare Stock After Q4 Earnings: Quiet Outperformer for 2026?
Addus HomeCare Corp (ADUS) recently reported strong Q4 earnings, outpacing the market while still trading below analyst targets. The company benefits from the demographic trend of an aging U.S. population opting for home care and maintains a solid balance sheet. Analysts are largely positive on ADUS, citing consistent execution and its role as a defensive growth stock in diversified portfolios.
Addus HomeCare Corporation (NASDAQ:ADUS) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have given Addus HomeCare Corporation (NASDAQ:ADUS) a "Moderate Buy" consensus recommendation, with an average 1-year price target of $134.33 from eleven firms. Despite recent insider selling totaling $1.804 million, institutional investors hold about 95.35% of the stock, with major holders like Capital Research and Vanguard increasing their positions. The company operates in home and community-based care services with a market cap of $1.92 billion and a P/E ratio of 19.87.
Addus HomeCare Corp Chairman and CEO Dirk Sells Shares
Addus HomeCare Corp's Chairman and CEO, Allison R. Dirk, sold 7,352 shares of common stock on February 24 and 25, 2026, for a total of $782,687. These sales were executed under a pre-established 10b5-1 plan to cover tax obligations from restricted stock awards. Following these transactions, Dirk directly holds 183,150 shares in the company.
Addus HomeCare (NASDAQ:ADUS) EVP Sells $31,608.00 in Stock
Addus HomeCare EVP Michael Wattenbarger sold 300 shares of ADUS stock for $31,608.00 on February 25th, reducing his stake by 3.08%. This follows other insider sales, including by CEO R. Dirk Allison, which can negatively impact investor sentiment, despite the company having a "Moderate Buy" consensus rating from analysts. The stock traded down 3.3% on higher-than-average volume, and institutional investors have recently adjusted their positions.
Darby Anderson Sells 396 Shares of Addus HomeCare (NASDAQ:ADUS) Stock
Darby Anderson, EVP of Addus HomeCare (NASDAQ:ADUS), sold 396 shares of the company's stock on February 25th at an average price of $105.36, and an additional 733 shares on February 24th, bringing his total holdings to 46,246 shares. These sales are part of a broader trend of insider selling, including significant sales by the CEO, occurring alongside increased short interest in the company. Despite positive Q4 earnings highlights and an average "Moderate Buy" analyst rating with an implied upside, these insider transactions and elevated short interest could lead to downward pressure on the stock.
Addus HomeCare (NASDAQ:ADUS) EVP Sells $18,648.72 in Stock
Addus HomeCare EVP Cliff Donald Blessing sold 177 shares of ADUS stock for $18,648.72 on February 25th, reducing his direct ownership to 12,361 shares. This sale follows another transaction on February 24th and is part of broader insider selling, including by CEO R. Dirk Allison, which could negatively impact sentiment. Despite the insider sales and recent price drops, analysts maintain a "Moderate Buy" consensus with a target price of $134.33, implying potential upside for the stock.
Addus HomeCare (NASDAQ:ADUS) EVP Sean Gaffney Sells 442 Shares
Addus HomeCare (NASDAQ:ADUS) EVP Sean Gaffney sold 442 shares on February 25th for $46,569.12, reducing his ownership by 2.15% to 20,080 shares. This sale follows another sale of 817 shares on February 24th and is part of broader insider selling that included CEO R. Dirk Allison and other senior EVPs, which may negatively pressure investor sentiment. Shares of Addus HomeCare traded down approximately 3.3% to $104.02, while analysts have a "Moderate Buy" consensus rating with a target price of $134.33.
Addus HomeCare (NASDAQ:ADUS) CEO Sells $249,071.04 in Stock
Addus HomeCare CEO R. Dirk Allison sold 2,364 shares of the company's stock for $249,071.04 on February 25th, and an additional 4,988 shares for $533,616.24 on February 24th, reducing his stake by 1.27%. These insider sales coincided with a 3.3% drop in ADUS stock to $104.02. Despite the sales, analysts maintain a "Moderate Buy" rating with a target price of $134.33, citing the company's Q4 revenue growth, margin leverage, and M&A growth strategy.
Addus HomeCare (NASDAQ:ADUS) EVP Sells $78,416.34 in Stock
Addus HomeCare (NASDAQ:ADUS) EVP Darby Anderson sold 733 shares of company stock for $78,416.34 on February 24th, followed by a sale of 396 shares on February 25th. This insider selling occurred amidst a 3.3% drop in ADUS shares, which traded below their 50- and 200-day moving averages. Despite recent insider sales, institutions hold 95.35% of the stock, and analysts maintain a "Moderate Buy" rating with a consensus price target suggesting notable upside.
Addus HomeCare (NASDAQ:ADUS) EVP Sells $46,754.63 in Stock
Addus HomeCare EVP Monica Raines sold 437 shares of stock for $46,754.63 on February 24th, and an additional 219 shares on February 25th, reducing her position by 3.02%. Other senior insiders, including CEO R. Dirk Allison, also conducted significant sales around the same dates, which could impact investor sentiment despite the routine nature of such transactions. The stock was trading at $104.02, with analysts holding a "Moderate Buy" consensus and an average target price of $134.33.
Truist reiterates Buy on Addus HomeCare stock, keeps $135 target By Investing.com
Truist Securities has reiterated a Buy rating on Addus HomeCare (NASDAQ:ADUS) and maintained a $135 price target, citing strong fourth-quarter results, improved margins, and growth in Personal Care and Hospice segments. The firm noted opportunities driven by rate momentum, solid labor trends, and the company's strong balance sheet for continued growth and M&A. InvestingPro analysis suggests the stock is currently undervalued relative to its Fair Value.
Addus Execs Anticipate Another Medicaid Rate Win, 80/20 Rule Repeal
Addus HomeCare Corporation executives anticipate the repeal of the Medicaid 80/20 rule and another round of state-level rate increases, following a successful 2025 with significant revenue boosts. A potential 4% to 5% rate increase in New Mexico is awaiting approval, and discussions are ongoing in Illinois. The company also reported strong Q4 2025 service revenue growth, driven largely by its personal care segment, and plans to expand its Addus Connect mobile app nationwide after a successful pilot in New Mexico.
Addus HomeCare (ADUS) EPS Jump Supports Bullish Narratives Despite Below‑Market Growth Forecasts
Addus HomeCare (ADUS) reported strong Q4 2025 results with significant EPS growth and a 30.3% earnings increase for the year, driven by acquisitions and efficiency improvements. Despite these positive indicators, future growth forecasts for revenue and earnings are more conservative, sitting below broader market expectations. The stock's current valuation, however, appears attractive with a P/E of 20x compared to an industry average of 76.8x and a DCF fair value significantly higher than its current price.
Addus HomeCare Corp SEC 10-K Report
Addus HomeCare Corp (ADUS) has released its 2025 Form 10-K report, detailing significant financial and operational growth, with net service revenues reaching $1,422.5 million, a 23.2% increase year-over-year. The company's growth strategy includes organic expansion and acquisitions, such as the Gentiva Acquisition and several smaller purchases, to broaden its geographical footprint and service offerings. Despite challenges from a competitive and regulated healthcare environment, including labor costs and integration risks, Addus is focused on high-quality care and leveraging technology for efficiency.
Earnings call transcript: Addus HomeCare reports strong Q4 2025 results
Addus HomeCare (ADUS) reported strong financial results for Q4 2025, exceeding EPS and revenue forecasts with $1.77 EPS and $373.1 million in revenue. Despite a 9.22% stock price drop in after-hours trading due to future growth concerns, the company highlighted 25.6% year-over-year revenue growth and increased adjusted EBITDA. Executives discussed strategic initiatives, including acquisitions, technology rollout, and legislative efforts, while addressing questions on labor markets, margin expansion, and compliance.
Addus HomeCare (ADUS) Shares Cross Below 200 DMA
Shares of Addus HomeCare Corp (ADUS) fell below their 200-day moving average of $112.67 on Tuesday, trading as low as $101.00 per share and currently down about 7.5% on the day. The stock's 52-week range is $88.96 to $124.435, with a last trade at $107.78. This event suggests a potential shift in the stock's short-term trend.
Addus HomeCare (ADUS) Beats Q4 Earnings and Revenue Estimates
Addus HomeCare (ADUS) exceeded Q4 earnings and revenue estimates, reporting $1.77 per share against an expected $1.71, and revenues of $373.08 million. The company has consistently surpassed EPS estimates over the last four quarters. Despite the positive results, the stock currently holds a Zacks Rank #3 (Hold), suggesting it will perform in line with the market in the near future.
Should Addus HomeCare’s Margin Gains and Earnings Beat Require Action From Addus HomeCare (ADUS) Investors?
Addus HomeCare Corporation reported strong Q4 and full-year 2025 results, with net income rising to US$95.91 million and diluted EPS to US$5.22. The company's adjusted Q4 EPS of US$1.77 and improved operating margins indicate increased efficiency, supporting the investment thesis for home and community-based care. Despite these positive results, the article suggests investors should consider ongoing risks such as potential reimbursement cuts and labor costs against the company's strong performance.
Addus HomeCare (ADUS) Beats Q4 Earnings and Revenue Estimates
Addus HomeCare (ADUS) reported strong Q4 earnings of $1.77 per share, surpassing the Zacks Consensus Estimate of $1.71, and revenues of $373.08 million, beating the estimate by 0.94%. The company has consistently exceeded EPS estimates over the last four quarters and has seen its shares increase by 7.5% year-to-date. While the stock currently holds a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market, its future performance will depend on management's outlook and industry trends.
Addus HomeCare: Q4 Earnings Snapshot
Addus HomeCare Corp. (ADUS) exceeded Wall Street expectations in its fourth-quarter earnings, reporting $29.8 million in net income, or $1.77 per share adjusted. The company's revenue reached $373.1 million, also surpassing analyst forecasts. For the full year, Addus HomeCare posted a profit of $95.9 million on $1.42 billion in revenue.
Addus HomeCare Corporation (ADUS) Releases Q4 2025 Earnings: Strong Revenue Growth but EPS Miss
Addus HomeCare Corporation (ADUS) reported strong revenue growth in Q4 2025, reaching $373.1 million, a 25.6% increase year-over-year, despite narrowly missing consensus estimates. Diluted earnings per share rose by 51.9% to $1.61 but also fell short of analyst predictions. The company's profitability metrics showed improvement, with gross margin at 33.2% and operating margin at 11.3%, indicating robust operating leverage.
Addus HomeCare (NASDAQ:ADUS) Reports Q4 CY2025 In Line With Expectations
Addus HomeCare (NASDAQ:ADUS) reported Q4 CY2025 results that met revenue expectations, with sales up 25.6% year-on-year to $373.1 million, and non-GAAP profit exceeding analyst estimates by 2.6% at $1.77 per share. The company achieved a record $1.4 billion in net service revenues for the full year, a 23.2% increase from 2024, driven by strong demand and favorable hiring trends. Its operating margin improved to 11.3%, and long-term EPS growth remained strong at 15.2% annually over five years.
Earnings Flash (ADUS) Addus HomeCare Corporation Reports Q4 Revenue $373.1M, vs. FactSet Est of $372.9M
Addus HomeCare Corporation (ADUS) reported Q4 revenue of $373.1 million, surpassing FactSet's estimate of $372.9 million. The company's business segments include Personal Care, Hospice, and Home Health services. Addus HomeCare provides non-medical assistance, terminal illness care, and medical services to individuals requiring support.
